Meeting
2016 Gastrointestinal Cancers Symposium
Germline pharmacogenomics in patients with dihydropyrimidine dehydrogenase (DPD) deficiency.
Authors
Moh'd M. Khushman
University of South Alabama, Mitchell Cancer Institute, Mobile, AL
Moh'd M. Khushman , Peter Joel Hosein , Daniel Cameron , David Roland Clarkson , Thomas Wayne Butler , Mary A. Vu , Carole Wiseman Norden , Wilma Baliem , Vanessa Jones , Sanjyot Bhadkamkar , Cindy Nelson , Frances Lee , Ajay Singh , William R. Taylor
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session C: Cancers of the Colon, Rectum, and Anus
Track
Cancers of the Colon, Rectum, and Anus
Sub Track
Prevention, Diagnosis, and Screening
Citation
J Clin Oncol 34, 2016 (suppl 4S; abstr 521)
DOI
10.1200/jco.2016.34.4_suppl.521
Abstract #
521
Poster Bd #
B12
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Quality Care Symposium
Implementing a high-reliability, system-wide program for pre-emptive DPD deficiency testing for patients planned for a systemic fluoropyrimidine.
First Author: Garrett Rompelman
Poster
2017 ASCO Annual Meeting
The potential clinical impact of pre-emptive screening of multiple polymorphisms in gene-encoding DPD on patients candidate for fluoropyrimidine based-chemotherapy: An experience of the Northern Italy Cancer Centre.
First Author: Francesco Iachetta
Poster
2023 ASCO Annual Meeting
Real-world experience of an in-house dihydropyrimidine dehydrogenase (DPYD) genotype test to guide fluoropyrimidine (FP) dosing at a multisite cancer hospital.
First Author: Jai Narendra Patel
Poster
2021 ASCO Annual Meeting
Pre-therapeutic dihydropyridimidine dehydrogenase (DPD) deficiency screening: Impact on fluoropyrimidine dose reduction at the second chemotherapy cycle and on early severe toxicity.
First Author: Côme De Metz